Jul. 30 at 2:52 PM
Raymond James assumed
$SRRK Strong Buy⬆️PT=
$53 was
$49 &said "While expectations are elevated ahead of apitegromab approval this fall, we are confident in the value proposition of apitegromab in SMA, with plenty of long-term optionality in the pipeline."
$RHHBY $BIIB $NVS $BHVN
Raymond James:
$SRRK's apitegromab, a mAb targeting latent myostatin, is progressing towards a Sept. 22 PDUFA date in spinal muscular atrophy (SMA), and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner—beyond SMA,
$SRRK's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential out-licensing and partnerships in the obesity space can offer another source of near-term optionality.